ライフサイエンスコーパス: monoclonal antibody

1 nts (eg, a MEK inhibitor and/or an anti-CD20 monoclonal antibody).

2 HAstV are resistant to a virus-neutralizing monoclonal antibody.

3 tform was modified with anti-E. coli O157:H7 monoclonal antibody.

4 ynthesised as peptides for the production of monoclonal antibody.

5 y, but no correlation with the anti-carp PAV monoclonal antibody.

6 d nanoparticles conjugated with an anti-CD38 monoclonal antibody.

7 recipient mice with anti-IP-10 neutralizing monoclonal antibody.

8 ould also be precipitated with a PS-specific monoclonal antibody.

9 ceptor-null mice that were administered GcgR monoclonal antibody.

10 ika virus with a highly specific immobilized monoclonal antibody.

11 ccine or treatment with one or a cocktail of monoclonal antibodies.

12 lbumin with nanomolar affinity for all three monoclonal antibodies.

13 cine development and the prophylactic use of monoclonal antibodies.

14 cloning and characterizing large numbers of monoclonal antibodies.

15 some inhibitors, immunomodulatory drugs, and monoclonal antibodies.

16 by a panel of amyloid conformation-specific monoclonal antibodies.

17 ations for biotherapies such as vaccines and monoclonal antibodies.

18 raxane) nanoparticles coated with commercial monoclonal antibodies.

19 chromatography resin during purification of monoclonal antibodies.

20 ome inhibitors, immunomodulatory agents, and monoclonal antibodies.

21 ity in extracellular recognition of GPCRs by monoclonal antibodies.

22 Monoclonal antibody 10-1074 targets the V3 glycan supers

23 Newly constructed monoclonal antibody, 1G6-D7, against the dual lysine reg

24 local administration at the inflamed site of monoclonal antibody 3-E7, which recognizes the pan-opioi

25 last enrichment technique to isolate a human monoclonal antibody, 46B8 that neutralizes all IBVs test

26 munoassay (CLIA) combining an Affimer with a monoclonal antibody (Affimer-MAb CLIA).

27 d by immunohistochemistry, using 2 different monoclonal antibodies against a major antigen of varicel

28 Neutralizing human monoclonal antibodies against alpha-toxin (AT) and clump

29 The affinity of the monoclonal antibodies against HLA-I beads confirmed the

30 Notably, monoclonal antibodies against PfCelTOS strongly inhibite

31 tive enzyme-linked immunosorbent assays with monoclonal antibodies against PfLDH or PfIDEh showed det

32 Monoclonal antibodies against proprotein convertase subt

33 While broadly cross-reactive, protective monoclonal antibodies against the haemagglutinin of infl

34 old chip containing an antifouling layer and monoclonal antibodies against the toxin and, after washi

35 The Fc-region of monoclonal antibodies against TNF has immunosuppressive

36 ion of aGVHD-associated lymphangiogenesis by monoclonal antibodies against vascular endothelial growt

37 A. marginale infection of host cells, but a monoclonal antibody against 6-sulfo-sLe(x) fails to inhi

38 Fetal hepatocytes were isolated using a monoclonal antibody against a hepatic surface protein, l

39 l characterization of a functional felinized monoclonal antibody against feline panleukopenia virus.

40 A previous study suggested that the 18B7 monoclonal antibody against glucuronoxylomannan (GXM), t

41 s have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly

42 ate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF.

43 A monoclonal antibody against Nogo-A showed a positive eff

44 Evolocumab is a fully human, monoclonal antibody against PCSK9 that reduces low-densi

45 during long-term therapy with evolocumab, a monoclonal antibody against proprotein convertase subtil

46 with PH were treated with Infliximab (IFX, a monoclonal antibody against TNF) and its impact on modul

47 Bevacizumab (Avastin(R)), a monoclonal antibody against vascular endothelial growth

48 Bevacizumab, a monoclonal antibody against VEGF, improves the proportio

49 osuppression with alemtuzumab (aIRR = 3.12), monoclonal antibodies (aIRR = 1.83), or polyclonal antib

50 holesterol (LDL-C) reductions with the PCSK9 monoclonal antibody alirocumab may be affected by backgr

51 or classes of effective agents in WM include monoclonal antibodies, alkylating agents, purine analogs

52 Monoclonal antibodies already in use or under investigat

53 d through radiolabeling of the anti-human TF monoclonal antibody (ALT-836) with (89)Zr.

54 p53 is inaccessible to classical therapeutic monoclonal antibodies, an increasingly successful class

55 proaches are emerging including antagonistic monoclonal antibodies and agonistic fusion proteins to i

56 asured by antigenic analysis with a panel of monoclonal antibodies and by detecting changes in oligom

57 nted in combination therapies with anti-CD20 monoclonal antibodies and open up novel avenues for the

58 ght into chemical degradation in full-length monoclonal antibodies and the high-resolution hydrogen-e

59 Monoclonal antibodies and vaccines targeting humoral res

60 the workflow to three-part assemblies for a monoclonal antibody and its single-chain antibody fragme

61 Different formats of an antibody (monoclonal antibody and the antigen binding fragments F(

62 ic approaches using biologics like vaccines, monoclonal antibodies, and enzymes.

63 cluding small molecules, proteins, vaccines, monoclonal antibodies, and nucleic acids.

64 hnique to express antigen-specific felinized monoclonal antibodies, and the initial characterization

65 ts who received daratumumab, a CD38-directed monoclonal antibody approved for the treatment of multip

66 IL-4c; recombinant IL-4 mixed with anti-IL-4 monoclonal antibody as a stabilizer) was administered af

67 1B/D agonist sumatriptan and a CGRP-blocking monoclonal antibody, attenuated the peripheral CGRP-indu

68 ents and collection of clinical samples, the monoclonal antibody based antigen detection method from

69 ment of improved therapeutic approaches, and monoclonal antibody-based drugs are potentially a powerf

70 t degree of specificity, particularly with a monoclonal antibody-based immunoassay.

71 lopment and technical validation of a rabbit monoclonal antibody-based sandwich immunoassay for human

72 that antisera from immunized mice inhibited monoclonal antibody binding to neutralizing epitopes.

73 Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB

74 demic, and induction of broadly neutralizing monoclonal antibodies (bNAbs) against HCV is a major goa

75 ethodology to characterize residual HCPs in (monoclonal) antibodies by combining a novel sample prepa

76 ecent clinical trials showing that anti-CGRP monoclonal antibodies can reduce and even prevent migrai

77 roprotein convertase subtilisin/kexin type 9 monoclonal antibodies can reduce low-density lipoprotein

78 of TcdB neutralization by PA41, a humanized monoclonal antibody capable of neutralizing TcdB from a

79 and then perfused with a humanized anti-CD47 monoclonal antibody (CD47mAb) in the treatment group or

80 culatory cessation, then flushed with a CD47 monoclonal antibody (CD47mAb) in the treatment group, or

81 EMENT Calcitonin gene-related peptide (CGRP) monoclonal antibodies (CGRP-mAbs) are capable of prevent

82 NT Recently, we reported that humanized CGRP monoclonal antibodies (CGRP-mAbs) prevent activation and

83 h to migraine treatment, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs) were developed to redu

84 new class of such drugs, humanized anti-CGRP monoclonal antibodies (CGRP-mAbs), were found to be effe

85 re the modified beads (mouse anti-flavivirus monoclonal antibody-coated beads) in the microfluidic ch

86 been made in the development of vaccines and monoclonal antibody cocktails that target the Ebola coat

87 Conclusion Targeted monoclonal antibody-conjugated HNPs can serve as a catal

88 Here, we optimize DNA-delivered monoclonal antibodies consisting of two potent human IgG

89 Blinatumomab, a bispecific monoclonal antibody construct that enables CD3-positive

90 An effective maternal RSV vaccine or monoclonal antibody could have a substantial effect on d

91 The DNA-delivered monoclonal antibodies decrease bacterial colonization of

92 These studies support DNA-delivered monoclonal antibodies delivery as a potential strategy t

93 A monoclonal antibody, designated LM26, binds to the cell

94 These monoclonal antibodies, developed against CTLA-4 and PD-1

95 tudy is to compare results associated with 3 monoclonal antibodies directed against the CD40/CD154 T

96 Monoclonal antibodies directed against tumor necrosis fa

97 y benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.

98 We investigated whether benralizumab, a monoclonal antibody directed against the alpha subunit o

99 Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Ralpha subu

100 Bevacizumab, a monoclonal antibody directed against VEGF, improves outc

101 e and db/db mice that were administered GcgR monoclonal antibody displayed lower blood glucose levels

102 dditional infectious pathogens.DNA-delivered monoclonal antibodies (DMAbs) can be produced by muscle

103 Among these, DNA-delivered monoclonal antibodies (DMAbs), produced by muscle cells

104 We previously described a monoclonal antibody (DX-2507) that binds to FcRn with hi

105 Treatment with the monoclonal antibody E06 or with apolipoprotein A-I mimet

106 Alemtuzumab, a CD52-depleting monoclonal antibody, effectively inhibits relapsing mult

107 The DNA-delivered monoclonal antibodies exhibit indistinguishable potency

108 ransducer functionalized with antidengue NS1 monoclonal antibodies for rapid detection of the dengue

109 Lymphoblasts were isolated using monoclonal antibodies for the Human Transferring Recepto

110 ning Bloch surface waves are tailored with a monoclonal antibody for highly specific biological recog

111 Idarucizumab, a monoclonal antibody fragment, was developed to reverse t

112 highlight the importance of CDCC and CDCP in monoclonal-antibody function and provide an experimental

113 DC-targeting vaccines, humanized recombinant monoclonal antibodies fused to Env gp140, were administe

114 izing the Ncad extracellular domain with the monoclonal antibody GC-4 suppresses lateral dispersal an

115 Therapy of cancer with radiolabeled monoclonal antibodies has produced impressive results in

116 he PD-1/PD-L1 immune checkpoint pathway with monoclonal antibodies has provided significant advances

117 Omalizumab, an anti-immunoglobulin E monoclonal antibody, has transformed the management of m

118 tinguished by amyloid conformation-dependent monoclonal antibodies have similarly distinct roles in p

119 ine (His-His) cross-links were discovered in monoclonal antibody HMW species.

120 ncement toward broader practical delivery of monoclonal antibody immunotherapeutics for additional in

121 rs are capable of outperforming high-quality monoclonal antibodies in a standard ELISA detection assa

122 Targeting CD30 with monoclonal antibodies in Hodgkin lymphoma (HL) and anapl

123 nderstanding the potential benefits of PCSK9 monoclonal antibodies incremental to statins in on-going

124 efficacy and safety of teprotumumab, a human monoclonal antibody inhibitor of IGF-IR, in patients wit

125 S-5745, a potent, highly selective humanized monoclonal antibody inhibitor of MMP9, has shown promise

126 ment from an antibody-drug conjugate and its monoclonal antibody intermediate.

127 We present a novel monoclonal antibody, IRAB-B, that is a specific, potent

128 The hydrophobicity of a monoclonal antibody is an important biophysical property

129 efficacy, and pharmacokinetics of anti-CD38 monoclonal antibody isatuximab given in 2 schedules (3,

130 A monoclonal antibody isolated from this cow harboured an

131 IIA (FcgammaRIIA), infusion of the HIT-like monoclonal antibody KKO increased fibrin and platelet de

132 Compared to conventional monoclonal antibodies, knob-into-hole bispecific antibod

133 o enable the detailed epitope mapping of two monoclonal antibodies known to recognize AGPs: JIM16 and

134 t given in combination with tumor-opsonizing monoclonal antibodies, KWAR23 greatly augments myeloid c

135 ized anticarcinoembryonic antigen (anti-CEA) monoclonal antibody, labetuzumab, can be used as a tumor

136 An anti-LigB monoclonal antibody library exhibits cell binding and ba

137 manized anti-folate receptor alpha (FRalpha) monoclonal antibody linked to the tubulin-disrupting may

138 Our group generated the monoclonal antibody mAb-A4 against human embryonic stem

139 Monoclonal antibodies (mAb) of anti-human IL-1b and anti

140 Agonistic monoclonal antibodies (mAb) targeting the T-cell recepto

141 er are promising epitopes for targeting with monoclonal antibodies (mAb).

142 rinciple of this method is based on the BChE monoclonal antibody (MAb) capable of acting as both capt

143 ng low side effect cancer therapy based on a monoclonal antibody (mAb) conjugated with a near-infrare

144 Eculizumab, a humanized anti-complement C5 monoclonal antibody (mAb) for treatment of paroxysmal no

145 Anti-DC-SIGN monoclonal antibody (MAb) inhibited HHV-8 infection of i

146 Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlapping epi

147 An IgG1 monoclonal antibody (mAb) purified by Protein A column e

148 inked, via lysine or cysteine residues, to a monoclonal antibody (mAb) scaffold.

149 th the F(ab')2 form of the anti-RSV G 131-2G monoclonal antibody (MAb) show that mutating the CX3C mo

150 en-printed electrode (AuSPE), and afterwards monoclonal antibody (mAb) specific to l-kynurenine was c

151 MEDI8852 is a novel monoclonal antibody (mAb) that neutralizes both group I

152 Experimental monoclonal antibody (mAb) therapies have shown promise f

153 CD73 on the activity of the anti-HER2/ErbB2 monoclonal antibody (mAb) trastuzumab.

154 of DC-STAMP in periodontitis, anti-DC-STAMP-monoclonal antibody (mAb) was tested in a mouse model of

155 Administration approved the first biosimilar monoclonal antibody (mAb), Inflectra/Remsima (Celltrion)

156 We isolated a human monoclonal antibody (mAb), ZKA190, that potently cross-n

157 -molecular weight (HMW) fractions of an IgG1 monoclonal antibody (mAb).

158 In recent years, monoclonal antibodies (mAbs) able to reinvigorate antitu

159 The classical view of therapeutic monoclonal antibodies (mAbs) against tumor-associated an

160 Monoclonal antibodies (mAbs) and antibody-related therap

161 r interaction with a group of alpha-JUNV GPC monoclonal antibodies (MAbs) and mouse antisera against

162 he ability to bind RBD-specific neutralizing monoclonal antibodies (MAbs) and the DPP4 receptor, and

163 l Hodgkin lymphoma (cHL) patients, anti-PD-1 monoclonal antibodies (mAbs) are increasingly being used

164 Monoclonal antibodies (mAbs) are large heterogeneous mol

165 Monoclonal antibodies (mAbs) are widely used and powerfu

166 Monoclonal antibodies (mAbs) can destroy tumors by recru

167 The Fc domain of IgG monoclonal antibodies (mAbs) contains two methionine res

168 In the course of screening monoclonal antibodies (MAbs) for their ability to delive

169 Intraperitoneally administered radiolabeled monoclonal antibodies (mAbs) have been tested in several

170 ir high affinities and specificities, rabbit monoclonal antibodies (mAbs) have demonstrated value and

171 Epitope mapping of the neutralizing monoclonal antibodies (mAbs) indicated major contacts wi

172 Recombinant monoclonal antibodies (mAbs) manufactured from immortali

173 undreds of labeled hybridoma cells producing monoclonal antibodies (mAbs) specific for a hapten were

174 Monoclonal antibodies (mAbs) targeting Notch protein act

175 is to evaluate the antibacterial activity of monoclonal antibodies (MAbs) targeting outer membrane pr

176 For Pseudomonas aeruginosa, human monoclonal antibodies (mAbs) targeting the Psl biofilm e

177 Two human monoclonal antibodies (MAbs) that neutralized DENV4 were

178 Using a panel of monoclonal antibodies (MAbs) that recognize known major

179 Here, we generated a panel of eight murine monoclonal antibodies (MAbs) utilizing a prime-boost vac

180 obtain large quantities of antigen-specific monoclonal antibodies (mAbs) were first established in t

181 and tumor delivery of a panel of anti-EphA2 monoclonal antibodies (mAbs) with and without drug conju

182 We report 3 LukAB-specific human monoclonal antibodies (mAbs) with distinct mechanisms of

183 mically conjugated to two different anti-HIV monoclonal antibodies (MAbs), anti-gp120 MAb 924 or anti

184 tibodies (PAbs) or RSV glycoprotein-specific monoclonal antibodies (MAbs), as determined by indirect

185 the design of antiviral therapies, including monoclonal antibodies (mAbs), have naturally relied exte

186 reened for antigenicity using four different monoclonal antibodies (MAbs), including PGT151.

187 wnregulation of CD20, a molecular target for monoclonal antibodies (mAbs), is a clinical problem lead

188 poA-I upon HDL formation, we developed novel monoclonal antibodies (mAbs).

189 nization through administration of exogenous monoclonal antibodies (mAbs).

190 es designed to initiate new responses (e.g., monoclonal antibodies [mAbs], chimeric antigen receptors

191 ave the potential to outperform conventional monoclonal antibodies, many bispecific antibodies have i

192 rains, so induction of multiple neutralizing monoclonal antibodies (NAbs) targeting distinct epitopes

193 passive immunization with human neutralizing monoclonal antibodies (nmAbs) has made exciting gains: (

194 t glucagon receptor (GCGR) inhibition with a monoclonal antibody normalized blood glucose and beta-hy

195 Therapeutic and diagnostic applications of monoclonal antibodies often require careful selection of

196 Cs) using the PDGFRalpha-specific inhibitory monoclonal antibody olaratumab.

197 The mechanism of action of PCSK9 monoclonal antibodies on lipoprotein metabolism remains

198 The human monoclonal antibody opicinumab (BIIB033, anti-LINGO-1) h

199 c blockade of FcRn-albumin interactions with monoclonal antibodies or peptide mimetics, which cause h

200 nancies or solid tumors by administration of monoclonal antibodies or T cells engineered to express c

201 s are not detected by conformation-sensitive monoclonal antibodies or through electron microscopy ana

202 Blockade, by either monoclonal antibody or tumor necrosis factor receptor ge

203 hat addition of an integrin beta1-activating monoclonal antibody, P4G11, to invasive colorectal cance

204 rformed structural studies on a neutralizing monoclonal antibody, PA50, a humanized mAb with both pot

205 resistant to the potent HAstV-2-neutralizing monoclonal antibody PL-2 (MAb PL-2).

206 e interaction between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of G

207 however, there are at least 50 vaccines and monoclonal antibody products in development, with those

208 Monoclonal antibodies provide an attractive alternative

209 The cognate antigen of a mouse monoclonal antibody raised against human Mregs was ident

210 utralization of asprosin in the blood with a monoclonal antibody reduced appetite and body weight in

211 Mepolizumab, an anti-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and

212 rolled intravenous delivery of a novel mouse monoclonal antibody replacement therapy, which acts as a

213 on SAB were determined using W6/32 and HC-10 monoclonal antibodies, respectively.

214 tment with anti-TNF-alpha or anti-IL-4Ralpha monoclonal antibodies restored the TH1- and TH2-induced

215 therapy prompted a trial with the anti-CD20 monoclonal antibody rituximab.

216 ing aggregate types and content in different monoclonal antibody samples.

217 e a novel approach to produce conformational monoclonal antibodies selected to specifically react wit

218 rolled protein-expressing cell lines using 6 monoclonal antibodies (SP142, E1L3N, 9A11, SP263, 22c3,

219 and -B35 expression on platelets using human monoclonal antibodies specific for these antigens.

220 y of tezepelumab (AMG 157/MEDI9929), a human monoclonal antibody specific for the epithelial-cell-der

221 was also shown to bind D25, a highly potent monoclonal antibody specific for the pre-F conformation.

222 of our method to analyze a high-purity NIST monoclonal antibody standard RM 8670 derived from a muri

223 Agonistic monoclonal antibodies targeting 4-1BB have been develope

224 In particular, the use of function blocking monoclonal antibodies targeting checkpoint inhibitors su

225 Although monoclonal antibodies targeting such ligands can block t

226 the envelope glycoprotein 1 (GP1) with JUNV monoclonal antibodies targeting the receptor binding sit

227 alf-life (eg, FVIII-Fc and PEGylated FVIII), monoclonal antibodies targeting tissue factor pathway in

228 Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene-related pe

229 of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed i

230 Canakinumab, a monoclonal antibody targeting interleukin-1beta, reduces

231 Avelumab, a human Ig-G1 monoclonal antibody targeting PD-L1 and approved in the

232 Pembrolizumab is a humanized monoclonal antibody targeting programmed cell death prot

233 hibit tumor growth in vitro and in vivo by a monoclonal antibody targeting the AGR2 self-dimerization

234 lular Hsp90alpha-Delta protein function by a monoclonal antibody targeting the fragment-5 region disr

235 -expressing xenografts, using the bispecific monoclonal antibody TF2 (anti-CEA x anti-histamine-succi

236 TGF-beta1-specific, humanized, neutralizing monoclonal antibody (TGF-beta1 mAb) is safe and more eff

237 for cancer are typically small molecules or monoclonal antibodies that act by inhibiting the activit

238 n immense interest in developing therapeutic monoclonal antibodies that act on GPCRs.

239 However, there is still a paucity of monoclonal antibodies that can cross-react between the g

240 Using epitope mapping, we discovered mouse monoclonal antibodies that can discriminate between huma

241 make possible the rapid development of human monoclonal antibodies that could become a potent immedia

242 Here, we obtained two anti-A(H1N1)pdm09 HA monoclonal antibodies that failed to neutralize viruses

243 Monoclonal antibodies that neutralize TcdB function have

244 Monoclonal antibodies that neutralize toxin activity pro

245 Here we present three separate monoclonal antibodies that specifically recognize Abetap

246 ted nearly identical binding profiles to HCV monoclonal antibodies that target conserved neutralizing

247 Girentuximab is a chimeric monoclonal antibody that binds carbonic anhydrase IX, a

248 PF-00547659 is a fully human monoclonal antibody that binds to human mucosal addressi

249 Avelumab (MSB0010718C) is a human IgG1 monoclonal antibody that binds to PD-L1, inhibiting its

250 nd by the Fab fragment of mAb35, a reference monoclonal antibody that causes experimental MG and comp

251 humanised, anti-interleukin 5 receptor alpha monoclonal antibody that directly and rapidly depletes e

252 inophilic, anti-interleukin-5 receptor alpha monoclonal antibody that has been shown to significantly

253 CAT-354) is an IL-13-neutralising human IgG4 monoclonal antibody that has shown clinical benefit in p

254 d risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by spec

255 anised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed d

256 Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase

257 We tested erenumab, a fully human monoclonal antibody that inhibits the calcitonin gene-re

258 Ocrelizumab is a humanized monoclonal antibody that selectively depletes CD20+ B ce

259 We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expre

260 BACKGROUND & AIMS: MEDI2070 is a human monoclonal antibody that selectively inhibits interleuki

261 Rilotumumab is a fully human monoclonal antibody that selectively targets the ligand

262 olavirus species, and the mechanism of these monoclonal antibody therapeutics is still not understood

263 negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CR

264 Although the advent of monoclonal antibody therapy has had a positive effect in

265 fficacy and the mechanisms of action of CD19 monoclonal antibody therapy in pediatric BCP-ALL, we tes

266 he complementary binding region on all three monoclonal antibodies to be the CDR H3 loop of the Fab r

267 The recent successful use of monoclonal antibodies to block immune regulatory pathway

268 , we evaluated the capacity of anti-receptor monoclonal antibodies to deliver vaccine components to s

269 evaluated the therapeutic activity of human monoclonal antibodies to DENV EDE for their ability to c

270 ither of these IVIG fragments, nor agonistic monoclonal antibodies to human Fas or Siglec-9 affected

271 We identify human monoclonal antibodies to O-antigens that are highly prot

272 the most widely used scaffold for developing monoclonal antibodies to treat human diseases.

273 Here we report studies using a monoclonal antibody to block IFN-alpha/beta receptor (IF

274 Inolimomab, a monoclonal antibody to CD25, has shown encouraging resul

275 An invasion inhibitory monoclonal antibody to CyRPA blocks binding of CyRPA to

276 erved even when the mice were treated with a monoclonal antibody to eliminate residual granulocyte ac

277 C) takes advantage of the selectivity of the monoclonal antibody to increase the efficacy of the chem

278 Evolocumab, a fully human monoclonal antibody to PCSK9 (proprotein convertase subt

279 Using a monoclonal antibody to plant cell wall xyloglucan, we sh

280 safety in the FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-

281 Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/

282 Infusion of a T-cell-depleting anti-CD8beta monoclonal antibody to the controller animals led to a s

283 Treatment of C57BL/6 or NOD mice with a monoclonal antibody to the CSF-1 receptor resulted in de

284 Treatment with the anti-ERBB2 humanized monoclonal antibody trastuzumab and chemotherapy signifi

285 effect of targeting this receptor using the monoclonal antibody TRC105, and find that in AML, TRC105

286 haracterize the epitope specificities of two monoclonal antibodies used in an ELISA for the quantific

287 A control monoclonal antibody used for 70 analyses over 450 days d

288 tested the binding breadth of the resulting monoclonal antibodies using a set of recombinant surface

289 In this study, a collection of high-affinity monoclonal antibodies was generated to boscalid.

290 A comprehensive suite of 155 monoclonal antibodies was used to monitor changes in dis

291 FG-3019, an anti-CTGF monoclonal antibody, was used to inhibit CTGF.

292 All patients receiving anti-PD-1 monoclonal antibodies were identified using the Mayo Can

293 ultifunctional HNPs conjugated with anti-MG1 monoclonal antibodies were synthesized, and the coupling

294 e inhibitory RGMa, clinically relevant human monoclonal antibodies were systemically administered aft

295 breadth of cross-reactive neutralization by monoclonal antibodies, whether engineered or isolated fr

296 sm of C. difficile toxin neutralization by a monoclonal antibody, which involves targeting a process

297 selective for the heavy and light chain of a monoclonal antibody, which when used consecutively, ensu

298 Combining biologic monoclonal antibodies with chemotherapeutic cytotoxic dr

299 anti-epidermal growth factor receptor (EGFR) monoclonal antibodies with radiotherapy (RT) to standard

300 the structure of the epitope recognized by a monoclonal antibody with opsonophagocytic activity and r